Related Experiment Video

Updated: Oct 1, 2025

Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study
07:50

Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study

Published on: April 18, 2025

457

A Bibliometric Analysis Based on Web of Science: Current Perspectives and Potential Trends of SMAD7 in Oncology

Xueying Huang1, Zhiying Yang1,2, Jinning Zhang1

  • 1Department of Histology and Embryology, Xiangya School of Medicine, Central South University, Changsha, China.

Frontiers in Cell and Developmental Biology
|March 7, 2022
PubMed

Insights

Research on SMAD7 in oncology is rapidly growing, with China leading publications. Future studies may focus on the interaction between PPAR-gamma and SMAD7 in cancer development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biotechnology

Background:

  • The number of publications on SMAD7 in oncology is rapidly increasing.
  • SMAD7 plays a crucial role in the crosstalk of multiple signaling pathways involved in carcinogenesis.
  • Understanding research trends, key contributors, and collaborations in SMAD7 oncology research is essential.

Purpose of the Study:

  • To conduct a bibliometric analysis of SMAD7 research in oncology from 2011-2020.
  • To identify dominant research topics, core authors, and collaborative networks.
  • To visualize the research landscape and identify future research directions.

Main Methods:

  • Bibliometric analysis of 3477 documents retrieved from the Web of Science Core Collection (2011-2020).
  • Utilized CiteSpace and VOSviewer for bibliometric visualization.
  • Included articles and reviews in English, excluding publications from 2021.

Main Results:

  • A significant annual increase in publications was observed.
  • China was the most prolific country, followed by the United States and Germany.
  • Lan Huiyao was identified as the most influential author; "PPAR-gamma" emerged as a key research hotspot.

Conclusions:

  • SMAD7 research in oncology is a continuously developing field.
  • Bibliometrics effectively visualizes research characteristics and trends.
  • The interaction between PPAR-gamma and SMAD7 in oncology presents a promising area for future investigation.
Keywords:
SMAD7VOSviewerbibliometricscitationcitespaceoncologyvisualizationweb of science

More Related Videos

Comparing Bibliometric Analysis Using PubMed, Scopus, and Web of Science Databases05:02

Comparing Bibliometric Analysis Using PubMed, Scopus, and Web of Science Databases

Published on: October 24, 2019

32.3K
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

9.1K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.1K